Silver-hollow mesoporous silica nanoparticles for clarithromycin delivery in an animal model of helicobacter pylori

Articles in Press

Document Type : Research Paper

Authors

1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Department of Pharmaceutics, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Background: Nanoparticle-based drug delivery systems offer a promising approach to overcoming antimicrobial resistance and enhancing therapeutic efficacy.
Objective(s): This study aimed to evaluate the efficacy of silver-hollow mesoporous silica nanoparticles (Ag-HMSNs) in the targeted delivery of clarithromycin for eradicating Helicobacter pylori (H. pylori).
Materials and Methods: A synergistic formulation comprising silver nanoparticles and clarithromycin-loaded hollow mesoporous silica nanoparticles (Ag-HMSNs@CLT) was examined for its antibacterial activity against H. pylori.  The effectiveness of various anti-H. pylori formulations was determined using in vitro inhibition assays and in vivo bacterial load reduction studies.
Results: The hollow mesoporous silica nanoparticles (HMSNs) demonstrated a high drug-loading capacity, with a clarithromycin content of 27%. The minimum inhibitory concentrations (MIC) for silver nanoparticles (Ag NPs), clarithromycin (CLT), and Ag-HMSNs@CLT were <2 μg/mL, <0.5 μg/mL, and <0.25 μg/mL, respectively. Among the tested formulations, Ag-HMSNs@CLT exhibited the most pronounced reduction in bacterial load during in vivo studies and significantly mitigated inflammation, as evidenced by hematoxylin-eosin staining.
Conclusion: The developed nanoparticle-based drug delivery system exhibited excellent drug-loading efficiency and controlled drug release over an extended period. This study highlighted the potential synergistic effects of combining anti-H. pylori agents and their efficacy in reducing bacterial growth and alleviating gastrointestinal complications associated with H. pylori infection.

Keywords

References

  1. 1. Judaki A, Rahmani A, Feizi J, Asadollahi K, Hafezi Ahmadi MR. Curcumin in combination with triple therapy regimes ameliorates oxidative stress and histopathologic changes in chronic gastritis-associated Helicobacter pylori Arq Gastroenterol. 2017;54(3):177-182.
  2. Zhang J, Chen Z, Kong J, Liang Y, Chen K, Chang Y, et al. Fullerenol nanoparticles eradicate Helicobacter pylori via pH-responsive peroxidase activity. ACS Appl Mater Interfaces. 2020;12(26).
  3. Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019;37(50):7295-7299.
  4. Al-Bahrani RM, Radif HM, Albaayit SF. Evaluation of potent silver nanoparticles production from Agaricus bisporus against Helicobacter pylori. Pak J Agric Sci. 2020;57:1197–1201.
  5. Almeida Furquim de Camargo B, Soares Silva DE, Noronha da Silva A, Campos DL, Machado Ribeiro TR, Mieli MJ, et al. New silver (I) coordination compound loaded into polymeric nanoparticles as a strategy to improve in vitro anti-Helicobacter pylori activity. Mol Pharm. 2020;17(7):2287-2298.
  6. Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release. 2016;224:86-102.
  7. Gopalakrishnan V, Masanam E, Ramkumar VS, Baskaraligam V, Selvaraj G. Influence of N‐acylhomoserine lactonase silver nanoparticles on the quorum sensing system of Helicobacter pylori: A potential strategy to combat biofilm formation. J Basic Microbiol. 2020;60(3):207-215.
  8. Pop R, Tăbăran AF, Ungur AP, Negoescu A, Cătoi C. Helicobacter Pylori-induced gastric infections: from pathogenesis to novel therapeutic approaches using silver nanoparticles. Pharmaceutics. 2022;14(7):1463.
  9. Sampath G, Govarthanan M, Krishnamurthy S, Nagarajan P, Rameshkumar N, Krishnan M, et al. Isolation and identification of metronidazole resistance Helicobacter pylori from gastric patients in the southeastern region of India and its advanced antibacterial treatment using biological silver oxide nanoparticles. Biochem Eng J. 2022;187:108445.
  10. Amin M, Hameed S, Ali A, Anwar F, Shahid SA, Shakir I, et al. Green synthesis of silver nanoparticles: structural features and in vivo and in vitro therapeutic effects against Helicobacter pylori induced gastritis. Bioinorg Chem Appl. 2014; (1):135824.
  11. Raza A, Sime FB, Cabot PJ, Maqbool F, Roberts JA, Falconer JR. Solid nanoparticles for oral antimicrobial drug delivery: A review. Drug Discov Today. 2019;24(3):858-866.
  12. Lu MM, Ge Y, Qiu J, Shao D, Zhang Y, Bai J, et al. Redox/pH dual-controlled release of chlorhexidine and silver ions from biodegradable mesoporous silica nanoparticles against oral biofilms. Int J Nanomedicine. 2018;13:7697-7709.
  13. Khosravian P, Khoobi M, Ardestani MS, Daryasari MP, Hassanzadeh M, Ghasemi-Dehkordi P, et al. Enhancement antimicrobial activity of clarithromycin by amine functionalized mesoporous silica nanoparticles as drug delivery system. Lett Drug Des Discov. 2018;15(7):787-795.
  14. Selvarajan V, Obuobi S, Ee PL. Silica nanoparticles—a versatile tool for the treatment of bacterial infections. Front Chem. 2020;8:602.
  15. Mirfakhraee S, Bafkary R, Ardakani YH, Dinarvand R. Synthesis of hyaluronic acid-grafted hollow mesoporous silica nanoparticles as nano-carriers for anticancer drug delivery. J Nanopart Res. 2022;24(5):100.
  16. Martínez-Carmona M, Gun’ko YK, Vallet-Regí M. Mesoporous silica materials as drug delivery:“The Nightmare” of bacterial infection. Pharmaceutics. 2018;10(4):279.
  17. Colilla M, Vallet-Regí M. Targeted stimuli-responsive mesoporous silica nanoparticles for bacterial infection treatment. Int J Mol Sci. 2020;21(22):8605.
  18. Gonzalez B, Colilla M, Diez J, Pedraza D, Guembe M, Izquierdo-Barba I, et al. Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment. Acta Biomater. 2018;68:261-271.
  19. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, et al. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep. 2014;4(1):5080.
  20. Lotfipour F, Valizadeh H, Hallaj-Nezhadi S, Milani M, Zakeri-Milani P. Comparison of microbiological and high-performance liquid chromatographic methods for determination of clarithromycin levels in plasma. Iran J Pharm Res.2010;9(1):27.

21.Werawatganon D. Simple animal model of Helicobacter pylori infection. World J Gastroenterol. 2014;20(21):6420.

  1. Frickenstein AN, Hagood JM, Britten CN, Abbott BS, McNally MW, Vopat CA, et al. Mesoporous silica nanoparticles: Properties and strategies for enhancing clinical effect. Pharmaceutics. 2021;13(4):570.
  2. Bruna T, Maldonado-Bravo F, Jara P, Caro N. Silver nanoparticles and their antibacterial applications. Int J Mol Sci. 2021;22(13):7202.
  3. Li X, Lenhart JJ. Aggregation and dissolution of silver nanoparticles in natural surface water. Environ Sci Technol. 2012;46(10):5378-5386.
  4. Tian Y, Qi J, Zhang W, Cai Q, Jiang X. Facile, one-pot synthesis, and antibacterial activity of mesoporous silica nanoparticles decorated with well-dispersed silver nanoparticles. ACS Appl Mater Interfaces. 2014;6(15):12038-12045.
  5. He X, Chen F, Chang Z, Waqar K, Hu H, Zheng X, et al. Silver mesoporous silica nanoparticles: fabrication to combination therapies for cancer and infection. Chem Rec. 2022;22(4):e202100287.
  6. Montalvo-Quirós S, Gómez-Graña S, Vallet-Regí M, Prados-Rosales RC, González B, Luque-Garcia JL. Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against Mycobacterium tuberculosis. Colloids Surf B Biointerfaces. 2021;197:111405.
  7. Wang X, Sun W, Yang W, Gao S, Sun C, Li Q. Mesoporous silica-protected silver nanoparticle disinfectant with controlled Ag+ ion release, efficient magnetic separation, and effective antibacterial activity. Nanoscale Adv. 2019;1(2):840-848.
  8. Sampath G, Shyu DJ, Rameshkumar N, Krishnan M, Sivasankar P, Kayalvizhi N. Synthesis and characterization of pyrogallol capped silver nanoparticles and evaluation of their in vitro anti-bacterial, anti-cancer profile against AGS cells. J Cluster Sci. 2021;32:549-557.

30.Purnawira B, Purwaningsih H, Ervianto Y, Pratiwi VM, Susanti D, Rochiem R, et al. Synthesis and characterization of mesoporous silica nanoparticles (MSNp) MCM 41 from natural waste rice husk. IOP Conf Ser Mater Sci Eng. 2019;541(1):012018.

  1. Li J, Ding Z, Li Y, Miao J, Wang W, Nundlall K, et al. Reactive oxygen species-sensitive thioketal-linked mesoporous silica nanoparticles as drug carrier for effective antibacterial activity. Mater Des. 2020;195:109021.
  2. Zhang Y, Zhi Z, Jiang T, Zhang J, Wang Z, Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release. 2010;145(3):257-263.

33.Kabiri F, Mirfakhraee S, Ardakani YH, Dinarvand R. Hollow mesoporous silica nanoparticles for co-delivery of hydrophobic and hydrophilic molecules: mechanism of drug loading and release. J Nanopart Res. 2021;23:1-4.

  1. Seljak KB, Kocbek P, Gašperlin M. Mesoporous silica nanoparticles as delivery carriers: An overview of drug loading techniques. J Drug Delivery Sci Technol. 2020;59:101906.

35.Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Varnamkhasti BS, Saboury AA. Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed Pharmacother. 2019;109:1100-1111.

  1. Saravanakumar K, Chelliah R, MubarakAli D, Oh DH, Kathiresan K, Wang MH. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori. Sci Rep. 2019;9(1):5787.

37.Gopinath V, Priyadarshini S, MubarakAli D, Loke MF, Thajuddin N, Alharbi NS, et al. Anti-Helicobacter pylori, cytotoxicity and catalytic activity of biosynthesized gold nanoparticles: multifaceted application. Arab J Chem. 2019;12(1):33-40.

  1. Attia HG, Albarqi HA, Said IG, Alqahtani O, Raey MA. Synergistic effect between amoxicillin and zinc oxide nanoparticles reduced by oak gall extract against Helicobacter pylori. Molecules. 2022;27(14):4559.
  2. Mansouri F, Saffari M, Moniri R, Sedaghat H, Moosavi GA, Molaghanbari M, et al. Investigation of the effect of silver nanoparticles alone and their combination with clarithromycin on H. pylori isolates. Available online: https://assets-eu.researchsquare.com/files/rs-1631922/v1/b64a9332-d940-4409-bb20-8e9716a7ebf8.pdf?c=1660802363 (accessed on 1 September 2024).

40.Villegas I, Rosillo MÁ, Alarcón-de-la-Lastra C, Vázquez-Román V, Llorente M, Sánchez S, et al. Amoxicillin and clarithromycin mucoadhesive delivery system for helicobacter pylori infection in a mouse model: Characterization, pharmacokinetics, and efficacy. Pharmaceutics. 2021;13(2):153.

41.Hadrup N, Loeschner K, Mortensen A, Sharma AK, Qvortrup K, Larsen EH, et al. The similar neurotoxic effects of nanoparticulate and ionic silver in vivo and in vitro. Neurotoxicology. 2012;33(3):416-423.

  1. Nallasamy V, Ramanathan S, Perumal P. In vivo evaluation of amoxicillin trihydrate and clarithromycin-loaded mucoadhesive microspheres for H. pylori eradication. Trop J Pharm Res. 2013;12(2):143-147.
  2. Ragab AE, Al-Madboly LA, Al-Ashmawy GM, Saber-Ayad M, Abo-Saif MA. Unravelling the in vitro and in vivo anti-Helicobacter pylori effect of delphinidin-3-O-glucoside rich extract from pomegranate exocarp: Enhancing autophagy and downregulating TNF-α and COX2. Antioxidants. 2022;11(9):1752.

 

Nanomedicine Journal

Articles in Press, Accepted Manuscript
Available Online from 13 May 2025

Files

Share

How to cite

Statistics